<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861780</url>
  </required_header>
  <id_info>
    <org_study_id>1810480-103</org_study_id>
    <nct_id>NCT03861780</nct_id>
  </id_info>
  <brief_title>Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation</brief_title>
  <official_title>Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professional Disposables International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Professional Disposables International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative Study of Antimicrobial Effectiveness Evaluation of 26ml Project X, 5.1ml Project&#xD;
      X and Prevantics Maxi Swabstick following ASTM E1173 - Standard Test Method for Evaluation of&#xD;
      Preoperative, Precatheterization, or Preinjection Skin Preparations, ASTM International, West&#xD;
      Conshohocken, Pennsylvania, 2015&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2019</start_date>
  <completion_date type="Actual">June 6, 2019</completion_date>
  <primary_completion_date type="Actual">June 6, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Samples are blinded to the participant and technical team</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bacterial Microflora on the Inguinal Area</measure>
    <time_frame>30 seconds</time_frame>
    <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Bacterial Microflora on the Inguinal Area</measure>
    <time_frame>10 minutes</time_frame>
    <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Bacterial Microflora on the Inguinal Area</measure>
    <time_frame>6 hours</time_frame>
    <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Bacterial Microflora on the Abdomen Area</measure>
    <time_frame>30 seconds</time_frame>
    <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Bacterial Microflora on the Abdomen Area</measure>
    <time_frame>10 minutes</time_frame>
    <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Bacterial Microflora on the Abdomen Area</measure>
    <time_frame>6 hours</time_frame>
    <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Bacteria Microflora Reduction</condition>
  <arm_group>
    <arm_group_label>Project X 26ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Project X 5.1ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevantics Maxi Swabstick</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Project X 26ml</intervention_name>
    <description>Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
    <arm_group_label>Project X 26ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Project X 5.1ml</intervention_name>
    <description>Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
    <arm_group_label>Project X 5.1ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevantics Maxi Swabstick</intervention_name>
    <description>Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
    <arm_group_label>Prevantics Maxi Swabstick</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects may be of either sex, at least 18 years of age, and of any race.&#xD;
&#xD;
          -  Subjects must be able to read and understand English.&#xD;
&#xD;
          -  Subjects must have read and signed an Informed Consent Form, Authorization to Use and&#xD;
             Disclose Protected Health Information Form, and List of Restricted Products prior to&#xD;
             participating in the study, all located in the separate Informed Consent documents.&#xD;
&#xD;
          -  Subjects must be in good general health and have no medical diagnosis of a physical&#xD;
             condition, such as a current or recent severe illness, medicated or uncontrolled&#xD;
             diabetes, hepatitis B, hepatitis C, an organ transplant, mitral valve prolapse with&#xD;
             heart murmur, fibromyalgia, ulcerative colitis, Crohn's disease, an immunocompromised&#xD;
             condition such as AIDS (or HIV positive), lupus, or medicated multiple sclerosis.&#xD;
&#xD;
          -  Subjects will have test sites on the skin of the abdomen and/or inguinal free of&#xD;
             injury and in good condition (no active skin rashes, excessive freckling, moles,&#xD;
             scratches, breaks in the skin, etc.) and have no currently active skin diseases or&#xD;
             skin conditions (for example, contact dermatitis, psoriasis or eczema) that may&#xD;
             compromise subject safety or study integrity.&#xD;
&#xD;
          -  Subjects must have skin within 6 inches of the test sites that is free of tattoos,&#xD;
             dermatoses, abrasions, cuts, lesions or other skin disorders. Subjects with tattoos,&#xD;
             scars, active skin rashes, or breaks in the skin of test sites, skin blemishes, such&#xD;
             as dry scabs or warts, may be admitted at the discretion of the Principal&#xD;
             Investigator, Subinvestigators, or Consulting Physicians.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergies to vinyl, latex (rubber), alcohols, metals, tapes or adhesives, inks,&#xD;
             sunscreens, deodorants, laundry detergents, topically applied fragrances, cleansers,&#xD;
             or to common antibacterial agents found in soaps or lotions, particularly&#xD;
             chlorhexidine gluconate or ethanol.&#xD;
&#xD;
          -  Have experienced hives (raised welts) as a reaction to anything that contacted the&#xD;
             skin.&#xD;
&#xD;
          -  Use of systemic or topical antibiotic medications during the 14-day pre-test period&#xD;
             through completion of testing on the single test day.&#xD;
&#xD;
          -  Use of systemic or topical steroids, other than for contraception, hormone therapy,&#xD;
             post-menopausal indications, during the 14-day pre-test period through completion of&#xD;
             testing on the single test day. This includes steroid medications used to treat&#xD;
             asthma. Note: topically applied hormonal steroids used for post-menopausal reasons&#xD;
             must not get on the test sites.&#xD;
&#xD;
          -  Any type of port (or portacath) or Peripherally Inserted Central Catheter (PICC).&#xD;
&#xD;
          -  Pregnancy, plans to become pregnant or impregnate a sexual partner within the pre-test&#xD;
             and test period of the study, or nursing a child. Female subjects must have a negative&#xD;
             urine pregnancy test documented before treatment with test materials.&#xD;
&#xD;
          -  Current participation or participation in a clinical study in the past 14 days.&#xD;
&#xD;
          -  Any medical condition or use of any medications that, in the opinion of the Principal&#xD;
             Investigator or consulting physicians, would preclude participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Collette Duley</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioScience Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioscience Laboratories Inc</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <results_first_submitted>June 17, 2021</results_first_submitted>
  <results_first_submitted_qc>October 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2021</results_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03861780/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>152 subjects were consented, randomized into the study, treated with test product and completed the study. Each subject is able to receive 2 test products (1 on each side of their body).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Project X 26ml</title>
          <description>3.15% w/v CHG / 70% v/v IPA contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Project X 26ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
        </group>
        <group group_id="P2">
          <title>Project X 5.1ml</title>
          <description>3.15% w/v CHG / 70% v/v IPA contained within a saturated at use applicator. 5.1ml volume. Single use.&#xD;
Project X 5.1ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
        </group>
        <group group_id="P3">
          <title>Prevantics Maxi Swabstick</title>
          <description>3.15% w/v CHG / 70% v/v IPA. Swabstick. Single use.&#xD;
Prevantics Maxi Swabstick: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Project X 26ml</title>
          <description>3.15% w/v CHG / 70% v/v IPA contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Project X 26ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
        </group>
        <group group_id="B2">
          <title>Project X 5.1ml</title>
          <description>3.15% w/v CHG / 70% v/v IPA contained within a saturated at use applicator. 5.1ml volume. Single use.&#xD;
Project X 5.1ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
        </group>
        <group group_id="B3">
          <title>Prevantics Maxi Swabstick</title>
          <description>3.15% w/v CHG / 70% v/v IPA. Swabstick. Single use.&#xD;
Prevantics Maxi Swabstick: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.1" lower_limit="18" upper_limit="87"/>
                    <measurement group_id="B2" value="43.4" lower_limit="18" upper_limit="87"/>
                    <measurement group_id="B3" value="44.7" lower_limit="18" upper_limit="87"/>
                    <measurement group_id="B4" value="43.4" lower_limit="18" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Bacterial Microflora on the Inguinal Area</title>
        <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
        <time_frame>30 seconds</time_frame>
        <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
        <group_list>
          <group group_id="O1">
            <title>Project X 26ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Project X 26ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O2">
            <title>Project X 5.1ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.&#xD;
Project X 5.1ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O3">
            <title>Prevantics Maxi Swabstick</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.&#xD;
Prevantics Maxi Swabstick: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bacterial Microflora on the Inguinal Area</title>
          <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
          <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
          <units>log10 CFU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>evaluable sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>evaluable sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="1.4"/>
                    <measurement group_id="O2" value="-3.1" spread="1.3"/>
                    <measurement group_id="O3" value="-3.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Bacterial Microflora on the Inguinal Area</title>
        <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
        <time_frame>10 minutes</time_frame>
        <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
        <group_list>
          <group group_id="O1">
            <title>Project X 26ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Project X 26ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O2">
            <title>Project X 5.1ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.&#xD;
Project X 5.1ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O3">
            <title>Prevantics Maxi Swabstick</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.&#xD;
Prevantics Maxi Swabstick: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bacterial Microflora on the Inguinal Area</title>
          <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
          <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
          <units>log10 CFU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>evaluable sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>evaluable sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="1.2"/>
                    <measurement group_id="O2" value="-3.2" spread="1.5"/>
                    <measurement group_id="O3" value="-3.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Bacterial Microflora on the Inguinal Area</title>
        <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
        <time_frame>6 hours</time_frame>
        <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
        <group_list>
          <group group_id="O1">
            <title>Project X 26ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Project X 26ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O2">
            <title>Project X 5.1ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.&#xD;
Project X 5.1ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O3">
            <title>Prevantics Maxi Swabstick</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.&#xD;
Prevantics Maxi Swabstick: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bacterial Microflora on the Inguinal Area</title>
          <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
          <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
          <units>log10 CFU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>evaluable sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>evaluable sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="1.3"/>
                    <measurement group_id="O2" value="-3.6" spread="1.5"/>
                    <measurement group_id="O3" value="-3.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Bacterial Microflora on the Abdomen Area</title>
        <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
        <time_frame>30 seconds</time_frame>
        <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
        <group_list>
          <group group_id="O1">
            <title>Project X 26ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Project X 26ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O2">
            <title>Project X 5.1ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.&#xD;
Project X 5.1ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O3">
            <title>Prevantics Maxi Swabstick</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.&#xD;
Prevantics Maxi Swabstick: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bacterial Microflora on the Abdomen Area</title>
          <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
          <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
          <units>log10 CFU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>evaluable sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>evaluable sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="1.1"/>
                    <measurement group_id="O2" value="-2.9" spread="1.1"/>
                    <measurement group_id="O3" value="-2.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Bacterial Microflora on the Abdomen Area</title>
        <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
        <time_frame>10 minutes</time_frame>
        <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
        <group_list>
          <group group_id="O1">
            <title>Project X 26ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Project X 26ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O2">
            <title>Project X 5.1ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.&#xD;
Project X 5.1ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O3">
            <title>Prevantics Maxi Swabstick</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.&#xD;
Prevantics Maxi Swabstick: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bacterial Microflora on the Abdomen Area</title>
          <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
          <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
          <units>log10 CFU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>evaluable sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>evaluable sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="1.2"/>
                    <measurement group_id="O2" value="-2.9" spread="1.1"/>
                    <measurement group_id="O3" value="-2.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Bacterial Microflora on the Abdomen Area</title>
        <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
        <time_frame>6 hours</time_frame>
        <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
        <group_list>
          <group group_id="O1">
            <title>Project X 26ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Project X 26ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O2">
            <title>Project X 5.1ml</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.&#xD;
Project X 5.1ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
          <group group_id="O3">
            <title>Prevantics Maxi Swabstick</title>
            <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.&#xD;
Prevantics Maxi Swabstick: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bacterial Microflora on the Abdomen Area</title>
          <description>Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention</description>
          <population>The overall number of participants analyzed represents the modified intent to treat (mITT) data set. The Participant Flow was is based on the intent to treat (ITT) dataset. Additionally, each subject is able to receive 2 test products (1 on each side of their body).</population>
          <units>log10 CFU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>evaluable sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>evaluable sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="1.0"/>
                    <measurement group_id="O2" value="-3.0" spread="1.0"/>
                    <measurement group_id="O3" value="-2.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Project X 26 mL</title>
          <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.&#xD;
Project X 26ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
        </group>
        <group group_id="E2">
          <title>Project X 5.1 mL</title>
          <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1 ml volume. Single use.&#xD;
Project X 5.1 ml: Application of antiseptic drug to the inguinal and abdomen areas of the subjects</description>
        </group>
        <group group_id="E3">
          <title>Prevantics Maxi Swabstick</title>
          <description>3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) Swabstick. Single use.&#xD;
Application of antiseptic drug to inguinal and abdomen areas of the subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Treatment Related AE</sub_title>
                <description>Study-related non-serious, Treatment Emergent AE</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator II/Training Coordinator</name_or_title>
      <organization>Bioscience Laboratories</organization>
      <phone>(406) 587-5735 ext 110</phone>
      <email>cduley@biosciencelabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

